NASDAQ:PLYX
Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. reported net income of −$9.0M in fiscal 2025. The diluted share count rose 32.8%.Summary generated from Polaryx Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−193.7%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+32.8%
Financials
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | n/a | n/a |
| Operating income | −4 | −8 |
| Net income | −30 | −9 |
| Free cash flow | n/a | n/a |
Recent filings
- 8-KResults of a shareholder vote
Sep 14, 2026 - 8-KRegulation FD disclosure
Sep 1, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - DEF 14AProxy statement
Jul 28, 2026 - 8-KDirector or officer change
Jul 21, 2026 - 8-KOther events
Jul 17, 2026 - 4Insider transaction report
May 28, 2026 - 8-KEntry into a material agreement
May 28, 2026